ESMO Preview: Opdivo Under Pressure

All eyes will be on beleaguered Opdivo at ESMO 2016 as BMS's leading checkpoint inhibitor comes under scrutiny in the NSCLC and renal cell cancer space. Details of Merck & Co's KEYNOTE-024 trial, Roche's Tecentriq in lung cancer and Exelixis' cabozantinib in kidney cancer could impact on how Opdivo's prospects are viewed.